{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T20:40:27Z","timestamp":1790628027967,"version":"4.1.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,8,23]]},"DOI":"10.7759\/cureus.67590","type":"journal-article","created":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T14:19:31Z","timestamp":1724422771000},"source":"Crossref","is-referenced-by-count":2,"title":["Gender Differences in the Clinical Profile of Sodium-Glucose Cotransporter-2 Inhibitor-Related Urinary Tract Infections"],"prefix":"10.7759","author":[{"given":"Mohammad Hayat","family":"Bhat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Salem","family":"Baba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md Ejaz","family":"Alam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abid Hussain","family":"Bhat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahnawaz","family":"Mir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basharat Qayoom","family":"Dar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoiab Mohd","family":"Patto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pooran","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/s41569-020-0406-8","article-title":"SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control","volume":"17","author":"Cowie MR","year":"2020","unstructured":"Cowie MR, Fisher M. SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control. Nat Rev Cardiol. 2020, 17:761-72. 10.1038\/s41569-020-0406-8","journal-title":"Nat Rev Cardiol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-023-01256-9","article-title":"Risk of urinary tract infection in patients with type 2 diabetes mellitus treated with dapagliflozin: a systematic review and meta-analysis of randomized controlled trials","volume":"43","author":"Zheng Z","year":"2023","unstructured":"Zheng Z, He D, Chen J, Xie X, Lu Y, Wu B, Jiang X. Risk of urinary tract infection in patients with type 2 diabetes mellitus treated with dapagliflozin: a systematic review and meta-analysis of randomized controlled trials. Clin Drug Investig. 2023, 43:209-25. 10.1007\/s40261-023-01256-9","journal-title":"Clin Drug Investig"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.4103\/ijem.IJEM_159_17","article-title":"Genital infections with sodium glucose cotransporter-2 inhibitors: occurrence and management in patients with type 2 diabetes mellitus","volume":"22","author":"Unnikrishnan AG","year":"2018","unstructured":"Unnikrishnan AG, Kalra S, Purandare V, Vasnawala H. Genital infections with sodium glucose cotransporter-2 inhibitors: occurrence and management in patients with type 2 diabetes mellitus. Indian J Endocrinol Metab. 2018, 22:837-42. 10.4103\/ijem.IJEM_159_17","journal-title":"Indian J Endocrinol Metab"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1186\/s12902-023-01464-6","article-title":"Association of SGLT-2 inhibitors with bacterial urinary tract infection in type 2 diabetes","volume":"23","author":"Tanr\u0131verdi M","year":"2023","unstructured":"Tanr\u0131verdi M, Ba\u015ftemir M, Demirbakan H, \u00dcnalan A, T\u00fcrkmen M, Tanr\u0131verdi G\u00d6. Association of SGLT-2 inhibitors with bacterial urinary tract infection in type 2 diabetes. BMC Endocr Disord. 2023, 23:211. 10.1186\/s12902-023-01464-6","journal-title":"BMC Endocr Disord"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3390\/medicines9120059","article-title":"The incidence and risk factors of urinary tract infection in patients with type 2 diabetes mellitus using SGLT2 inhibitors: a real-world observational study","volume":"9","author":"Uitrakul S","year":"2022","unstructured":"Uitrakul S, Aksonnam K, Srivichai P, Wicheannarat S, Incomenoy S. The incidence and risk factors of urinary tract infection in patients with type 2 diabetes mellitus using SGLT2 inhibitors: a real-world observational study. Medicines (Basel). 2022, 9:59. 10.3390\/medicines9120059","journal-title":"Medicines (Basel)"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s10741-023-10363-w","article-title":"Adverse effects of sodium-glucose cotransporter-2 inhibitors in patients with heart failure: a systematic review and meta-analysis","volume":"29","author":"Pozzi A","year":"2024","unstructured":"Pozzi A, Cirelli C, Merlo A, et al.. Adverse effects of sodium-glucose cotransporter-2 inhibitors in patients with heart failure: a systematic review and meta-analysis. Heart Fail Rev. 2024, 29:207-17. 10.1007\/s10741-023-10363-w","journal-title":"Heart Fail Rev"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13820","article-title":"Sodium glucose cotransporter 2 inhibitors and risk of genital mycotic and urinary tract infection: a population-based study of older women and men with diabetes","volume":"21","author":"Lega IC","year":"2019","unstructured":"Lega IC, Bronskill SE, Campitelli MA, et al.. Sodium glucose cotransporter 2 inhibitors and risk of genital mycotic and urinary tract infection: a population-based study of older women and men with diabetes. Diabetes Obes Metab. 2019, 21:2394-404. 10.1111\/dom.13820","journal-title":"Diabetes Obes Metab"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.21720","article-title":"Frequency of urinary tract infections in type 2 diabetic patients taking dapagliflozin","volume":"14","author":"Khan S","year":"2022","unstructured":"Khan S, Hashmi MS, Rana MA, Zafar GM, Asif S, Farooq MT, Zahoor S. Frequency of urinary tract infections in type 2 diabetic patients taking dapagliflozin. Cureus. 2022, 14:e21720. 10.7759\/cureus.21720","journal-title":"Cureus"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1256548","article-title":"Comparative safety of different recommended doses of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes mellitus: a systematic review and network meta-analysis of randomized clinical trials","volume":"14","author":"Chen L","year":"2023","unstructured":"Chen L, Xue Q, Yan C, Tang B, Wang L, Zhang B, Zhao Q. Comparative safety of different recommended doses of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes mellitus: a systematic review and network meta-analysis of randomized clinical trials. Front Endocrinol (Lausanne). 2023, 14:1256548. 10.3389\/fendo.2023.1256548","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.aace.2022.04.002","article-title":"Emphysematous cystitis and urinary retention in a male patient with diabetes mellitus type 2 treated with empagliflozin","volume":"8","author":"Brock GM","year":"2022","unstructured":"Brock GM, Lane SM, Roosevelt TS. Emphysematous cystitis and urinary retention in a male patient with diabetes mellitus type 2 treated with empagliflozin. AACE Clin Case Rep. 2022, 8:163-5. 10.1016\/j.aace.2022.04.002","journal-title":"AACE Clin Case Rep"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.pcd.2017.06.004","article-title":"Clinical risk factors predicting genital fungal infections with sodium-glucose cotransporter 2 inhibitor treatment: the ABCD nationwide dapagliflozin audit","volume":"12","author":"Thong KY","year":"2018","unstructured":"Thong KY, Yadagiri M, Barnes DJ, et al.. Clinical risk factors predicting genital fungal infections with sodium-glucose cotransporter 2 inhibitor treatment: the ABCD nationwide dapagliflozin audit. Prim Care Diabetes. 2018, 12:45-50. 10.1016\/j.pcd.2017.06.004","journal-title":"Prim Care Diabetes"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.maturitas.2021.06.003","article-title":"Age- and sex-specific risk of urogenital infections in patients with type 2 diabetes treated with sodium-glucose co-transporter 2 inhibitors: a population-based self-controlled case-series study","volume":"150","author":"Kang M","year":"2021","unstructured":"Kang M, Heo KN, Ah YM, Yang BR, Lee JY. Age- and sex-specific risk of urogenital infections in patients with type 2 diabetes treated with sodium-glucose co-transporter 2 inhibitors: a population-based self-controlled case-series study. Maturitas. 2021, 150:30-6. 10.1016\/j.maturitas.2021.06.003","journal-title":"Maturitas"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2022.109816","article-title":"Risk factors of first and recurrent genitourinary tract infection in patients with type 2 diabetes treated with SGLT2 inhibitors: a retrospective cohort study","volume":"186","author":"Lin YH","year":"2022","unstructured":"Lin YH, Lin CH, Huang YY, Tai AS, Fu SC, Chen ST, Lin SH. Risk factors of first and recurrent genitourinary tract infection in patients with type 2 diabetes treated with SGLT2 inhibitors: a retrospective cohort study. Diabetes Res Clin Pract. 2022, 186:109816. 10.1016\/j.diabres.2022.109816","journal-title":"Diabetes Res Clin Pract"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2012.06.008","article-title":"Incidence of urinary tract infection among patients with type 2 diabetes in the UK General Practice Research Database (GPRD)","volume":"26","author":"Hirji I","year":"2012","unstructured":"Hirji I, Guo Z, Andersson SW, Hammar N, Gomez-Caminero A. Incidence of urinary tract infection among patients with type 2 diabetes in the UK General Practice Research Database (GPRD). J Diabetes Complications. 2012, 26:513-6. 10.1016\/j.jdiacomp.2012.06.008","journal-title":"J Diabetes Complications"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2014.06.009","article-title":"Risk characterization for urinary tract infections in subjects with newly diagnosed type 2 diabetes","volume":"28","author":"Fu AZ","year":"2014","unstructured":"Fu AZ, Iglay K, Qiu Y, Engel S, Shankar R, Brodovicz K. Risk characterization for urinary tract infections in subjects with newly diagnosed type 2 diabetes. J Diabetes Complications. 2014, 28:805-10. 10.1016\/j.jdiacomp.2014.06.009","journal-title":"J Diabetes Complications"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1186\/s40001-022-00644-9","article-title":"The prevalence of urinary tract infections in type 2 diabetic patients: a systematic review and meta-analysis","volume":"27","author":"Salari N","year":"2022","unstructured":"Salari N, Karami MM, Bokaee S, Chaleshgar M, Shohaimi S, Akbari H, Mohammadi M. The prevalence of urinary tract infections in type 2 diabetic patients: a systematic review and meta-analysis. Eur J Med Res. 2022, 27:20. 10.1186\/s40001-022-00644-9","journal-title":"Eur J Med Res"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.4103\/ijem.IJEM_566_18","article-title":"Adverse effect profile and effectiveness of sodium glucose co-transporter 2 inhibitors (SGLT2i) - a prospective real-world setting study","volume":"23","author":"Gill HK","year":"2019","unstructured":"Gill HK, Kaur P, Mahendru S, Mithal A. Adverse effect profile and effectiveness of sodium glucose co-transporter 2 inhibitors (SGLT2i) - a prospective real-world setting study. Indian J Endocrinol Metab. 2019, 23:50-5. 10.4103\/ijem.IJEM_566_18","journal-title":"Indian J Endocrinol Metab"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14064","article-title":"Hyperglucosuria induced by dapagliflozin augments bacterial colonization in the murine urinary tract","volume":"22","author":"Saenkham P","year":"2020","unstructured":"Saenkham P, Jennings-Gee J, Hanson B, Kock ND, Adams LG, Subashchandrabose S. Hyperglucosuria induced by dapagliflozin augments bacterial colonization in the murine urinary tract. Diabetes Obes Metab. 2020, 22:1548-55. 10.1111\/dom.14064","journal-title":"Diabetes Obes Metab"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2013.05.004","article-title":"Urinary tract infections in patients with diabetes treated with dapagliflozin","volume":"27","author":"Johnsson KM","year":"2013","unstructured":"Johnsson KM, Ptaszynska A, Schmitz B, Sugg J, Parikh SJ, List JF. Urinary tract infections in patients with diabetes treated with dapagliflozin. J Diabetes Complications. 2013, 27:473-8. 10.1016\/j.jdiacomp.2013.05.004","journal-title":"J Diabetes Complications"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.aace.2023.06.001","article-title":"Emphysematous kidney related to the use of empagliflozin in a diabetic woman","volume":"9","author":"Echeverria P","year":"2023","unstructured":"Echeverria P, Saa J, Paz Y Mi\u00f1o LD. Emphysematous kidney related to the use of empagliflozin in a diabetic woman. AACE Clin Case Rep. 2023, 9:136-9. 10.1016\/j.aace.2023.06.001","journal-title":"AACE Clin Case Rep"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2017-219335","article-title":"Caution advised with dapagliflozin in the setting of male urinary tract outlet obstruction","volume":"2017","author":"Hall V","year":"2017","unstructured":"Hall V, Kwong J, Johnson D, Ekinci EI. Caution advised with dapagliflozin in the setting of male urinary tract outlet obstruction. BMJ Case Rep. 2017, 2017:bcr2017219335. 10.1136\/bcr-2017-219335","journal-title":"BMJ Case Rep"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.6803","article-title":"Recurrent urinary tract infection associated with SGLT-2 inhibitor in type 2 diabetes mellitus patient: a case report","volume":"11","author":"Hazique M","year":"2023","unstructured":"Hazique M, Surana A, Sinha M, Anand A. Recurrent urinary tract infection associated with SGLT-2 inhibitor in type 2 diabetes mellitus patient: a case report. Clin Case Rep. 2023, 11:e6803. 10.1002\/ccr3.6803","journal-title":"Clin Case Rep"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/264355-gender-differences-in-the-clinical-profile-of-sodium-glucose-cotransporter-2-inhibitor-related-urinary-tract-infections","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T14:19:34Z","timestamp":1724422774000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/264355-gender-differences-in-the-clinical-profile-of-sodium-glucose-cotransporter-2-inhibitor-related-urinary-tract-infections"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,23]]},"references-count":22,"URL":"https:\/\/doi.org\/10.7759\/cureus.67590","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8,23]]}}}